Literature DB >> 24746031

Trends in acute myocardial infarction event rates and risk of recurrences after an incident event in Norway 1994 to 2009 (from a Cardiovascular Disease in Norway Project).

Gerhard Sulo1, Stein Emil Vollset2, Ottar Nygård3, Jannicke Igland4, Grace M Egeland2, Marta Ebbing5, Grethe S Tell2.   

Abstract

We explored trends in acute myocardial infarction (AMI) event rates in Norway during 1994 to 2009 and trends in the 6-month, 1-year, and 3-year risk of recurrences after an incident AMI during 2001 to 2008 in men and women ≥25 years. Trends in AMI event rates (incident and recurrent) were analyzed using joinpoint regression analyses and expressed as annual percentage change (APC) in rates. Trends in AMI recurrences were explored using conditional risk models for ordered events in Cox regression. Analyses were stratified by gender and age group. Overall, AMI rates were stable during 1994 to 2002 but declined during 2002 to 2009 (APC = -2.0; 95% confidence interval [CI] -3.1 to -0.9 in men; APC = -2.1; 95% CI -3.8 to -0.5 in women). In the younger age group, rates declined during the whole study period in men (APC = -0.6; 95% CI -1.0 to -0.3) but not in women. Among older patients, no changes were observed during 1994 to 2002, whereas rates declined during 2002 to 2009 (APC = -2.6; 95% CI -3.8 to -1.4 in men; APC = -2.4; 95% CI -4.0 to -0.7 in women). During 2001 to 2008, in the older age group, the 6-month, 1-year, and 3-year risks of recurrences were reduced annually by 4.7%, 4.3%, and 5.4% in men and 5.2%, 5.0%, and 5.7% in women (all ptrend <0.001), respectively. No changes were observed in the younger age group. In conclusion, favorable trends in AMI event rates and recurrences observed in Norway were mostly seen among patients aged 65+ years, whereas less favorable trends were observed among younger patients, especially among women.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24746031     DOI: 10.1016/j.amjcard.2014.03.006

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Unfavourable risk factor control after coronary events in routine clinical practice.

Authors:  Elise Sverre; Kari Peersen; Einar Husebye; Erik Gjertsen; Lars Gullestad; Torbjørn Moum; Jan Erik Otterstad; Toril Dammen; John Munkhaugen
Journal:  BMC Cardiovasc Disord       Date:  2017-01-21       Impact factor: 2.298

2.  Pharmacologically treated diabetes and hospitalization among older Norwegians receiving homecare services from 2009 to 2014: a nationwide register study.

Authors:  Anne-Siri Fismen; Jannicke Igland; Tonje Teigland; Grethe Seppola Tell; Truls Ostbye; Johannes Haltbakk; Marit Graue; Kare I Birkeland; Mark Peyrot; Marjolein Memelink Iversen
Journal:  BMJ Open Diabetes Res Care       Date:  2021-03

3.  Long-term hospital-based secondary prevention of coronary artery disease: a randomized controlled trial.

Authors:  Anete Kaldal; Serena Tonstad; Jarle Jortveit
Journal:  BMC Cardiovasc Disord       Date:  2021-12-16       Impact factor: 2.298

4.  Examining the lower range of the association between alcohol intake and risk of incident hospitalization with atrial fibrillation.

Authors:  Inger Ariansen; Eirik Degerud; Knut Gjesdal; Grethe S Tell; Øyvind Næss
Journal:  Int J Cardiol Heart Vasc       Date:  2020-11-29

5.  Clinical Profile and Management of Patients with Incident and Recurrent Acute Myocardial Infarction in Albania - a Call for More Focus on Prevention Strategies.

Authors:  Sokol Myftiu; Enxhela Sulo; Genc Burazeri; Bledar Daka; Ilir Sharka; Artan Shkoza; Gerhard Sulo
Journal:  Zdr Varst       Date:  2017-10-09

6.  Casual blood glucose and subsequent cardiovascular disease and all-cause mortality among 159 731 participants in Cohort of Norway (CONOR).

Authors:  Hilde Kristin Refvik Riise; Jannicke Igland; Gerhard Sulo; Marit Graue; Johannes Haltbakk; Grethe Seppola Tell; Marjolein Memelink Iversen
Journal:  BMJ Open Diabetes Res Care       Date:  2021-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.